본문으로 바로가기 주메뉴 바로가기

사용자별 맞춤메뉴

자주찾는 메뉴

추가하기
닫기

연구성과

contents area

detail content area

Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID
  • 작성일2021-02-08
  • 최종수정일2021-02-08
  • 담당부서연구기획과
  • 연락처043-719-8033
  • 70


Scientific Reports, 2020.10, 16200-0, DOI: https://doi.org/https://doi.org/10.1038/s41598-020-72879-7


Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19

Junhyung Cho, Young Jae Lee; Je Hyoung Kim; Sang il Kim; Sung Soon Kim; Byeng-Sun Choi; Jang-Hoon Choi


Abstract

    The current coronavirus (COVID-19) pandemic is exacerbated by the absence of effective therapeutic agents. Notably, patients with COVID-19 and comorbidities such as hypertension and cardiac diseases have a higher mortality rate. An efficient strategy in response to this issue is repurposing drugs with antiviral activity for therapeutic effect. Digoxin (DIG) and ouabain (OUA) are FDA drugs for heart diseases that have antiviral activity against several coronaviruses. Thus, we aimed to assess antiviral activity of DIG and OUA against SARS-CoV-2 infection. The half-maximal inhibitory concentrations (IC50) of DIG and OUA were determined at a nanomolar concentration. Progeny virus titers of single-dose treatment of DIG, OUA and remdesivir were approximately 103-, 104- and 103-fold lower (> 99% inhibition), respectively, than that of non-treated control or chloroquine at 48 hours post-infection (hpi). Furthermore, therapeutic treatment with DIG and OUA inhibited over 99 % of SARS-CoV-2 replication, leading to viral inhibition at the post entry stage of the viral life cycle. Collectively, these results suggest that DIG and OUA may be an alternative treatment for COVID-19, with potential additional therapeutic effects for patients with cardiovascular disease.



  • 본 연구는 질병관리본부 연구개발과제연구비를 지원받아 수행되었습니다.
  • This research was supported by a fund by Research of Korea Centers for Disease Control and Prevention.



본 공공저작물은 공공누리  출처표시 조건에 따라 이용할 수 있습니다 본 공공저작물은 공공누리 "출처표시" 조건에 따라 이용할 수 있습니다.
TOP